Research use only. Read more

Growth Hormone

PEG-MGF

A polyethylene-glycol-conjugated MGF variant investigated for circulating an MGF-like signal systemically rather than only at the site of mechanical stress.

Also known as: Pegylated MGF

Quick facts

Molecular weight

5,000 Da

Half-life

60 h

Frequency

twice weekly

Admins / wk

2

Routes

SubQ

Typical dose

200 mcg–200 mcg

Mechanism & positioning

A polyethylene-glycol-conjugated MGF variant investigated for circulating an MGF-like signal systemically rather than only at the site of mechanical stress.

Researched for: extended muscle-repair signalling, systemic MGF distribution.

Reconstitution defaults

Default vial

5 mg

BAC water

2 mL

Concentration

2500 mcg/mL

Doses per vial

~25

Calculate with this peptide

Documented pairwise interactions

  • warning

    PEG-MGF + MGF

    Short-acting and pegylated forms of the same MGF molecule; combining them stacks receptor activity without literature support.

References

  • Hill M, Goldspink G, J Physiol, 2003.

Related peptides in the Growth Hormone class

Frequently asked questions about PEG-MGF

What is the typical research dose range for PEG-MGF?
PEG-MGF is most commonly investigated at 200 mcg–200 mcg per administration, twice weekly. Note: twice to thrice weekly. These values reflect documented research-stage protocols and are not medical recommendations.
What is the half-life of PEG-MGF?
PEG-MGF has an approximate plasma half-life of 60 hours. Practical steady state is reached after roughly five half-lives — about 13 days under continuous administration.
How is PEG-MGF administered in research protocols?
Published research uses subq administration. Typical reconstitution is 5 mg vial in 2 mL of bacteriostatic water, producing a concentration of 2500 mcg/mL.
What vial sizes are commonly available for PEG-MGF?
Common stocked vial sizes are 5 mg. The 5 mg vial is the most-used default in published protocols.